RxDoctor Payments Data

Peter Acosta, MD

Family Medicine · Boerne, TXNPI 1083637888

Payments from drug & device makers

$398in general payments, 2019–2025

Across 10 payments — averaging $39.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$122
  • Acadia Pharmaceuticals Inc$91
  • Lilly USA, LLC$59
  • Urovant Sciences Inc$43
  • Neurocrine Biosciences, Inc.$21
  • Novartis$19
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$398 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$405,638
Medicare patients
446
Services billed
3,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate60$183,264
EliquisApixaban411$124,347
MyrbetriqMirabegron118$28,435
XareltoRivaroxaban81$23,085
FarxigaDapagliflozin Propanediol76$21,658
TrulicityDulaglutide26$20,961
JardianceEmpagliflozin58$19,364
TradjentaLinagliptin68$17,716
TivicayDolutegravir Sodium15$16,925
XifaxanRifaximin11$16,392
JanuviaSitagliptin Phosphate57$16,134
Nurtec OdtRimegepant Sulfate14$14,927
Bydureon BciseExenatide Microspheres21$14,587
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog78$13,734
Divalproex Sodium313$11,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$122$206,349141 claims
Lilly USA, LLCTrulicity, Olanzapine$59$24,467176 claims
NovartisEntresto$19$8,98631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →